Work

HSR25-159: Real-World Effectiveness of First-Line Osimertinib for Patients in the US With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer Who Were Eligible for Medicare

Year: 2025

Type: article

Source: Journal of the National Comprehensive Cancer Network

DOI: 10.6004/jnccn.2024.7278

Authors: Pritesh S. Karia, Yan Kwan Lau, Darren Thomas, Rachel Salomonsen, Rahul Shenolikar

Institutions: AstraZeneca (United States), AstraZeneca (United Kingdom)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4408929305

FWCI:

Cites:

Cited by:

Related to: 10